Aktie A2PH4J NAVIDEA BIOPHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Navidea Biopharmaceuticals, Inc.

Aktien

A2PH4J

US63937X2027

NAVB

Verzögert OTC Markets
Andere Börsenplätze
 18:32:34 02.05.2024 		% 5 Tage % 1. Jan.
0,035 USD 0,00 % Intraday Chart für Navidea Biopharmaceuticals, Inc. -4,89 % -36,59 %
2023 Navidea Biopharmaceuticals, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI
2023 Sektor Update: Gesundheitswesen MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding
Navidea: Q3 Earnings Snapshot
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index
Sector Update: Health Care
Top Midday Decliners
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
Navidea Biopharmaceuticals, Inc. Announces Executive Changes
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. Announces Board Changes
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PH4J Aktie
  4. Nachrichten Navidea Biopharmaceuticals, Inc.
  5. Andere Sprachen